Clinical significance of serum soluble intercellular adhesion molecule 1 in gastric cancer.
暂无分享,去创建一个
T. Sawada | M. Yashiro | K. Hirakawa | K. Maeda | T. Sunami | B. Nakata | T. Hori | T. Ishikawa | Y. Ogawa | Y. Kato | K. Hirakawa | T. Ishikawa | T. Hori | Takeshi Sunami | Kiyoshi Maeda | Y. Kato
[1] I. Adachi,et al. Serum levels of soluble intercellular adhesion molecule-1 and E-selectin in metastatic breast carcinoma: correlations with clinicopathological features and prognosis. , 1999, International journal of oncology.
[2] G. Hasçelik,et al. Circulating intercellular adhesion molecule-1 and E-selectin levels in gastric cancer. , 1998, British Journal of Cancer.
[3] N. Tanaka,et al. Soluble intercellular adhesion molecule-1 and natural killer cell activity in gastric cancer patients. , 1998, Research communications in molecular pathology and pharmacology.
[4] A. Grothey,et al. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. , 1998, British Journal of Cancer.
[5] J. Roh,et al. Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. , 1998, Yonsei medical journal.
[6] M. Jones,et al. Circulating soluble adhesion molecules E-cadherin, E-selectin, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in patients with gastric cancer. , 1997, British Journal of Cancer.
[7] J. Krutmann,et al. Analysis of the production of soluble ICAM-1 molecules by human cells. , 1996, Experimental hematology.
[8] M. Minemura,et al. Serum concentration of intercellular adhesion molecule–1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis , 1995, Hepatology.
[9] Enzo Galligioni,et al. Expression and release of intercellular adhesion molecule‐1 in renal‐cancer patients , 1995, International journal of cancer.
[10] A. Alexandrov,et al. Expression and shedding of ICAM‐1 in bladder cancer and its immunotherapy , 1993, International journal of cancer.
[11] N. Yanagisawa,et al. Increases levels of circulating intercellular adhesion molecule‐1 in multiple sclerosis and human T‐lymphotropic virus type I‐associated myelopathy , 1993, Annals of neurology.
[12] J. Becker,et al. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.
[13] R. Rothlein,et al. A form of circulating ICAM-1 in human serum. , 1991, Journal of immunology.
[14] R. Rothlein,et al. Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma. , 1991, Cancer research.
[15] Timothy A. Springer,et al. Adhesion receptors of the immune system , 1990, Nature.
[16] Michael Loran Dustin,et al. The arrangement of the immunoglobulin-like domains of ICAM-1 and the binding sites for LFA-1 and rhinovirus , 1990, Cell.
[17] Michael Loran Dustin,et al. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families , 1988, Cell.